Novacyt S A Cdi — Australian approval for Yourgene® DPYD Assay

Novacyt secures TGA approval for Yourgene DPYD test, targeting a A$3–12m Australian market.

What the company is saying

Novacyt S.A. announces that, as of 11 November 2026, it has received TGA approval to supply the Yourgene Insight DPYD in vitro diagnostic for clinical use in Australia. The company emphasizes that this approval converts the assay from Research Use Only status, following IVDR certification in September 2026. The release highlights the assay’s ability to detect 19 DPYD variants and positions this as a key differentiator. Novacyt quantifies the Australian addressable market at 16,000 to 66,000 tests per year, with a current Medicare reimbursement rate of approximately A$182 per test. The company frames the opportunity as an annual reimbursed market value of approximately A$3.0 million to A$12.0 million for laboratories, underscoring the near-term commercial revenue potential. The announcement is focused on regulatory and commercial milestones, with no mention of realised sales, contracts, or customer uptake.

What the data suggests

The announcement provides concrete regulatory milestones: TGA approval on 11 November 2026 and IVDR certification in September 2026. The Yourgene Insight DPYD assay is now cleared for clinical use in Australia, moving beyond Research Use Only status. The assay detects 19 DPYD variants, which is presented as a technical advantage. The estimated Australian addressable market is 16,000 to 66,000 tests per year, with a Medicare reimbursement of about A$182 per test. This implies a potential annual reimbursed market value of A$3.0 million to A$12.0 million for laboratories. All financial figures are projections based on market size and reimbursement rates, not actual sales or contracts. No realised revenue, orders, or uptake data are disclosed, so the figures represent theoretical opportunity rather than demonstrated commercial traction.

Analysis

The announcement is upbeat, highlighting the TGA approval as a significant regulatory milestone and quantifying the potential Australian market opportunity for the Yourgene® Insight DPYD assay. The realised facts are the regulatory approvals (TGA and IVDR) and the technical capability of the assay. However, all financial figures (market size, reimbursement rate, annual market value) are forward-looking estimates based on addressable market assumptions, not actual sales or contracts. The company claims the approval 'extends near-term commercial revenue potential,' but provides no evidence of realised revenue, orders, or customer commitments. The tone is moderately promotional, focusing on opportunity rather than achievement. There is no indication of a large capital outlay or immediate earnings impact, so capital intensity is not flagged. The gap between narrative and evidence lies in the extrapolation from regulatory approval to commercial success, without supporting data on uptake or financial performance.

Risk flags

• ●Commercial uptake risk is high, as all financial projections are based on addressable market estimates rather than signed contracts or demonstrated demand. Without evidence of laboratory adoption, the projected A$3.0–12.0 million annual market remains hypothetical.
• ●Competitive and reimbursement risk exists if alternative assays or changes in Medicare policy reduce the effective market size or reimbursement rate. The company’s figures assume current policy and no disruptive competition.
• ●Disclosure risk is present because the announcement omits any realised sales, customer commitments, or specific commercial rollout timelines, making it difficult to assess the likelihood or speed of revenue conversion.

Bottom line

Novacyt’s TGA approval for the Yourgene Insight DPYD assay opens the door to the Australian clinical diagnostics market, with a stated addressable opportunity of 16,000–66,000 tests per year at A$182 each. This translates to a theoretical annual market of A$3.0–12.0 million for laboratories, but no actual sales, contracts, or uptake data are disclosed. The announcement is credible on regulatory progress but relies entirely on projected, not realised, commercial impact. Investors should treat the opportunity as unproven until orders or revenue figures are reported. The key issue to watch is whether laboratories begin adopting the test and if Novacyt can capture a meaningful share of the projected market.

Announcement summary

(LSE:NCYT) Novacyt S.A. announced that it received TGA approval on 11 November 2026 to supply the Yourgene® Insight DPYD in vitro diagnostic for clinical use in Australia. This approval converts the Yourgene® Insight DPYD assay from Research Use Only status following IVDR certification in September 2026. The Yourgene® Insight DPYD assay is designed to detect 19 DPYD variants. The company estimates the Australian addressable market for this assay is between 16,000 and 66,000 tests per year. The current Medicare reimbursement rate for the test is approximately A$182 per test. Based on these figures, the annual reimbursed market value to laboratories is estimated at approximately A$3.0 million to A$12.0 million. This approval extends the near-term commercial revenue potential for Novacyt in Australia. The transition from Research Use Only to clinical use is enabled by the IVDR certification achieved in September 2026. The TGA approval date is specifically 11 November 2026. The company highlights the significance of the Australian market opportunity for the Yourgene® Insight DPYD assay. The product's ability to detect 19 DPYD variants is a key feature. The company is positioning the assay for clinical use following regulatory milestones. The announcement quantifies both the test volume opportunity and the associated reimbursed market value. The company is targeting laboratories as the primary customers for the assay in Australia. The approval is expected to drive commercial revenue in the near term.

Disagree with this article?